Featured Content
Amgen will buy Celgene's blockbuster psoriasis treatment Otezla for $13.4 billion in cash, according to The Wall Street Journal.
Amgen will buy Celgene's blockbuster psoriasis treatment Otezla for $13.4 billion in cash, according to The Wall Street Journal.